A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201A, An Anti-HER2-Antibody Drug Conjugate, Versus Ado-Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated with Trastuzumab and Taxane (CTMS# 18-0080)
Lay Description
Category
- Cancers and Other Neoplasms
- Breast
- IRB Number
- 20180830HU
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- No
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Frances Crawford
(210) 450-5037
crawfordf1@uthscsa.edu
Sonia Creighton
(210) 450-1366
creighton@uthscsa.edu
Virginia Kaklamani
(210) 450-3838
kaklamani@uthscsa.edu
Myrna Montenegro
(210) 450-5954
montenegro@uthscsa.edu
Courtney Nichols
(210) 450-1794
nicholsc2@uthscsa.edu
Mailbox Ctrc Regulatory Affairs
regaffapp@uthscsa.edu
Regulatory Staff
regaffstaff@uthscsa.edu
Kathleen Rodriguez
(210) 450-1365
rodriguezk3@uthscsa.edu
Benjamin Schleif
(210) 450-1366
schleifb@uthscsa.edu
Morgan Seekatz
(210) 450-1133
seekatz@uthscsa.edu
Principal Investigator
Virginia Kaklamani